A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer

HIGHLIGHTS

• who: Yingbo Shao from the Sun Yat-sen University Cancer Center (SYSUCC), China have published the research: A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer, in the Journal: (JOURNAL) of March/15,/2022
• what: All the patients included in this study had received at least two lines of rescue therapy, so anlotinib was given as third-line in 19 (40.4%) patients, and as forth-line or above therapy in 28 (59.6%) patients. In the present study, patients who received anlotinib . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.